This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adachi K, Katsube T, Kawamura A et al (2000) CYP 2C19 genotype status and intragastric pH during dosing with lasoprazole and rabeprazole. Aliment Pharmacol Ther 14: 1259–1266
Armstrong D, Marshall JK, Chiba N et al (2004) Canadian consensus conference on the management of gastroesophageal reflux disease in adults — update 2004. Can J Gastroenterol 19: 15–35
Armstrong D, Talley NJ, Lauritsen K et al (2004) The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomperazole and omeprazole. Aliment Pharmacol Ther 20: 413–436
Armstrong D, Veldhuizenvan Zanten SJO, Barkun AN et al (2005) Heartburn-dominant, univestigated dyspepsia: a comparison of “PPI-start” and “H2-RA-start” management strategy in primary care — the CADETHR study. Aliment Pharmacol Ther 21: 1189–1202
Blum AL, Martinek J (1999) Interactions of proton pump inhibitors and Helicobacter pylori in vivo. In: Proton pump inhibitors (Olbe L, ed). Basel Boston London: Birkhäuser, pp 130–141
Caro JJ, Salas M, Ward A (2001) Healing and relapse rates in gastroesophageal reflux disease treated with newer proton pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 23: 998–1017
Cantu P, Carmagnola S, Savojardo D, Aloca M, Penagini R (2003) Effect of non-selective gamma-aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects. Aliment Pharmacol Ther 18: 699–704
Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L (1997) Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 11: 473–482
Ciccaglione AF, Marzio L (2003) Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 52: 464–470
Chiba N, de Gara CJ, Wilkinson JM, Hunt RH (1997) Speed of healing and symptom relief in grade-II to-IV gastroesophageal reflux disease: a meta-analysis. Gastroenetrology 112: 1798–1810
Dent J, Brun J, Fendrick AM et al (1999) An evidence-based appraisal of reflux disease management — the Genval Workshop Report. Gut 44(Suppl. 2): 1–16
DeVault KR, Castell DO (1999) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenetrol 94: 1434–1442
Donnellan C, Sharma N, Preston C, Moayyedi P (2005) Medical treatments for maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2: CD 003245
Eriksson S, Langström G, Rikner L, Carlsson R, Naesdal J (1995) Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenetrol Hepatol 7: 467–475
Fass, R, Shapiro M, Dekel R, Sewell J (2005) Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease — where next? Aliment Pharmacol Ther 22: 79–94
Howden CW, Henning JM, Huang B, Lukasik N, Freston JW (2001) Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 96: 1704–1710
Klok RM, Postma MJ, van Hout BA, Brouwers JR (2003) Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 17: 1237–1245
Koeck GH, Sifrim D, Lerut T, Janssens J, Tack J (2003) Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52: 1397–1402
Koop H, Katschinski M, Arnold R (1991) Konservative Behandlung der floriden peptischen Ösophagusstenose. Vollständige Beseitigung durch Bougeirung und Omeprazol bei H2-Blocker-refraktären Fällen. Med Klin 86: 566–568
Koop H, Schepp W, Müller-Lissner S et al (2005) Gastroösophageale Refluxkrankheit — Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten. Z Gastroenterol 43: 163–194
Labenz J, Armstrong D, Lauritsen K et al (2005) A randomised comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagtis: the EXPO study. Aliment Pharmacol Ther 21: 739–746
Meining A, Classen M (2000) The role of diet an lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 95: 2692–2697
Sandvik AK, Brenna E, Waldum HL (1997) Review article: the pharmacological inhibition of acid secretion — tolerance and rebound. Aliment Pharmacol Ther 11: 1013–1018
Sifrim D, Holloway RH, Silny J, Tack J, Lerut T, Janssens J (2001) Composition of the postprandial refluxate in patients with gastro-esophageal reflux disease. Amer J Gastroenterol 96: 647–655
Silvis SE, Farahmand M, Johnson JA, Ansel HJ, Ho SB (1996) A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic reflux. Gastrointest Endoc 43: 216–221
Smith PM, Kerr GD, Cockel R et al (1994) A comparison of omeprazole and ranitidine in the prevention of recurrance of benign esophageal stricture. Restore Investigator Group. Gastroenterology 107: 1545–1548
Thomson AB, Barkun AN, Armstrong D et al (2003) The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Emperiric Therapy — Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 17: 1481–1491
Tytgat GN, Heading RC, Müller-Lissner S et al (2003) Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 18: 291–301
van Pinxteren B, Numans ME, Bonis PA, Lau J (2004) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux-like symptoms and endoscopy negative reflux disease. Cochrane Database Sys Rev 4: CD 002095
Vela MF, Tutuian R, Katz PO, Castell DO (2003) Baclofen decreases acid and non-acid post-prandial gastroesophageal reflux measured by combined multi-channel intraluminal impedance and pH. Aliment Pharmacol Ther 17: 243–251
Vela MF, Camacho-Lubato L, Srinivasan R, Tutuian R, Katz PO, Castel DO (2001) Simultaneous intra-esophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenetrology 120: 1599–1806
Venables TL, Newland RD, Patel AC, Hole J, Wicock C, Turbitt ML (1997) Omeprazole 10 milligrams once daily, omeprazole 20 mg once daily, or ranitidine 150 twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general pratice. Scand J Gastroenterol 32: 965–973
Vigneri S, Termini R, Leandro G et al (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106–1110
Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352: 2211–2221
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag/Wien
About this chapter
Cite this chapter
Koop, H. (2006). Medical Therapy of Gastro-Oesophageal Reflux Disease. In: Granderath, F.A., Kamolz, T., Pointner, R. (eds) Gastroesophageal Reflux Disease. Springer, Vienna. https://doi.org/10.1007/3-211-32317-1_9
Download citation
DOI: https://doi.org/10.1007/3-211-32317-1_9
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-23589-8
Online ISBN: 978-3-211-32317-5
eBook Packages: MedicineMedicine (R0)